Table 2 Correlation of ZC3H15 expression with clinicopathological variables in TGGA datasets.

From: ZC3H15 promotes gastric cancer progression by targeting the FBXW7/c-Myc pathway

Clinicopathological features

Cases

ZC3H15 expression

F

P

Low

%

High

%

Age

<60

134

79

59.0

55

41.0

8.009

0.005

≥60

278

119

42.8

159

57.2

Gender

Male

273

135

49.5

138

50.5

2.042

0.154

Female

144

66

45.8

78

54.2

H. pylori infection

Negative

164

56

34.1

108

65.9

0.499

0.481

Positive

21

10

47.6

11

52.4

Depth of invasion

T1

24

10

41.7

14

58.3

3.207

0.023

T2

90

54

60.0

36

40.0

T3

189

86

45.5

103

54.5

T4

111

51

46.0

60

54.0

Lymph node metastasis

N0

130

66

50.8

64

49.2

0.935

0.424

N1

114

55

48.2

59

51.8

N2

86

38

44.2

48

55.8

N3

77

39

50.6

38

49.4

Distant metastasis

M0

374

178

47.6

196

52.4

0.294

0.588

M1

22

14

63.6

8

36.4

Histologic Grade

G1

10

5

50.0

5

50.0

4.042

0.018

G2

153

61

39.9

92

60.1

G3

245

131

53.5

114

46.5

Grade

Stage I

58

31

53.4

27

46.6

1.738

0.159

Stage II

138

71

51.4

67

48.6

Stage III

174

75

43.1

99

56.9

Stage IV

34

19

55.9

15

44.1